Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Neumeister, P; Schulz, E; Pansy, K; Szmyra, M; Deutsch, AJ.
Targeting the Microenvironment for Treating Multiple Myeloma.
Int J Mol Sci. 2022; 23(14): 7627
Doi: 10.3390/ijms23147627
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Neumeister Peter
- Co-Autor*innen der Med Uni Graz
- Deutsch Alexander
- Pansy Katrin
- Schulz Eduard
- Szmyra-Polomka Marta Malwina
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Multiple myeloma (MM) is a malignant, incurable disease characterized by the expansion of monoclonal terminally differentiated plasma cells in the bone marrow. MM is consistently preceded by an asymptomatic monoclonal gammopathy of undetermined significance, and in the absence of myeloma defining events followed by a stage termed smoldering multiple myeloma (SMM), which finally progresses to active myeloma if signs of organ damage are present. The reciprocal interaction between tumor cells and the tumor microenvironment plays a crucial role in the development of MM and the establishment of a tumor-promoting stroma facilitates tumor growth and myeloma progression. Since myeloma cells depend on signals from the bone marrow microenvironment (BMME) for their survival, therapeutic interventions targeting the BMME are a novel and successful strategy for myeloma care. Here, we describe the complex interplay between myeloma cells and the cellular components of the BMME that is essential for MM development and progression. Finally, we present BMME modifying treatment options such as anti-CD38 based therapies, immunomodulatory drugs (IMiDs), CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates which have significantly improved the long-term outcome of myeloma patients, and thus represent novel therapeutic standards.
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies, Bispecific - therapeutic use
- Bone Marrow - pathology
- Humans - administration & dosage
- Monoclonal Gammopathy of Undetermined Significance - pathology
- Multiple Myeloma - pathology
- Tumor Microenvironment - administration & dosage
- Find related publications in this database (Keywords)
- microenvironment
- multiple myeloma
- immunology
- targeted therapy
- CD 38 antibody therapy
- daratumumab
- isatuximab
- CAR T cell
- bispecific antibody